{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:49:35Z","timestamp":1788997775969,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.rpth.2026.106649","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:06:48Z","timestamp":1778580408000},"page":"106649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Shaping hemophilia care: lessons and legacy of the SIPPET trial after 10 years"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Palla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Garagiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106649_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106649_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1055\/s-0037-1615621","article-title":"Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis","volume":"85","author":"White","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106649_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib5","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1182\/blood-2010-09-308668","article-title":"Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom","volume":"117","author":"Hay","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.thromres.2018.05.027","article-title":"Risk factors for inhibitor development in severe hemophilia A","volume":"168","author":"Garagiola","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106649_bib7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1538-7836.2004.00710.x","article-title":"The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977\u201399","volume":"2","author":"Darby","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.70039","article-title":"Trends in treatment of severe haemophilia and impact on inhibitor assessment by the EUHASS Registry","volume":"31","author":"Fischer","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib9","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"Randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106649_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jth.13888","article-title":"Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis","volume":"16","author":"Peyvandi","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.5482\/HAMO-16-10-0040","article-title":"Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?","volume":"37","author":"Berntorp","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.106649_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13239","article-title":"SIPPET trial: the answers","volume":"23","author":"Makris","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib13","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/hae.13133","article-title":"Do the SIPPET study results apply to the patients I treat?","volume":"23","author":"Fischer","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/hae.13203","article-title":"SIPPET: methodology, analysis and generalizability","volume":"23","author":"Peyvandi","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3324\/haematol.2017.174706","article-title":"Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A","volume":"103","author":"Calvez","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106649_bib16","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Gouw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106649_bib18","article-title":"Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 previously untreated patients from Europe and Canada","volume":"7","author":"Fisher","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group","volume":"328","author":"Lusher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106649_bib20","first-page":"2428","article-title":"A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group","volume":"83","author":"Bray","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib21","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1160\/TH15-04-0273","article-title":"Factor VIII products in haemophilia A: one size fits all?","volume":"113","author":"Mannucci","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib22","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2014-07-586347","article-title":"Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A","volume":"124","author":"Calvez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib23","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2014-07-580498","article-title":"Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib24","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/s-0033-1356715","article-title":"Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update","volume":"39","author":"Franchini","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106649_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH14-07-0621","article-title":"Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis","volume":"113","author":"Marcucci","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib27","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1055\/s-0040-1722623","article-title":"Simoctocog alfa (Nuwiq) in previously untreated patients with severe haemophilia A: final results of the NuProtect study","volume":"121","author":"Liesner","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.13883","article-title":"Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial","volume":"26","author":"Yaish","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/hae.15151","article-title":"Extension study with rVIII-singlechain in previously untreated patients (PUPs) with severe haemophilia A","volume":"31","author":"Mahlangu","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib30","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1182\/blood.2021013563","article-title":"First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results","volume":"139","author":"K\u00f6nigs","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17474086.2023.2247160","article-title":"Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study","volume":"16","author":"Sidonio","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106649_bib32","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.jtha.2023.07.030","article-title":"The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results","volume":"21","author":"Kenet","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/hae.13806","article-title":"Impact of the survey of inhibitors in plasma-product exposed toddlers (SIPPET) study and its post hoc analyses on clinical practice in the United States: a survey of Haemophilia and Thrombosis Research Society members","volume":"25","author":"Sande","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib34","first-page":"283","article-title":"Italian consumption of plasma-derived factor VIII after the SIPPET study","volume":"15","author":"Traversa","year":"2017","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2026.106649_bib35","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/hae.13400","article-title":"After the SIPPET study: position paper of the CoMETH, the French society of haemophilia","volume":"24","author":"Lebreton","year":"2018","journal-title":"Haemophilia"},{"issue":"Suppl 6","key":"10.1016\/j.rpth.2026.106649_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib38","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.jtha.2024.05.026","article-title":"International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology","volume":"22","author":"Rezende","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102595","article-title":"Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study","volume":"8","author":"Miri","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib40","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3324\/haematol.2018.206383","article-title":"Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?","volume":"104","author":"Varthaman","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106649_bib41","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2017.07.001","article-title":"To serve and protect: the modulatory role of von Willebrand factor on factor VIII immunogenicity","volume":"31","author":"Hartholt","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2026.106649_bib42","first-page":"2436","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","volume":"109","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106649_bib43","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Haemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib44","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1182\/blood-2017-06-791756","article-title":"Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis","volume":"130","author":"Rosendaal","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/jth.13961","article-title":"Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement","volume":"16","author":"Spena","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib46","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1538-7836.2009.03636.x","article-title":"Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A","volume":"7","author":"Pavlova","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib47","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannav\u00f2","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106649_bib48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/bjh.17249","article-title":"IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A","volume":"192","author":"Peyvandi","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106649_bib49","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/bloodadvances.2023011388","article-title":"Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort","volume":"8","author":"Hassan","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106649_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102858","article-title":"Survey of Inhibitors in Plasma-Product Exposed Toddlers Study Group. Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates","volume":"9","author":"Chand","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106649_bib51","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/hae.14325","article-title":"Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/hae.12566","article-title":"Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A","volume":"21","author":"Hashemi","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106649_bib53","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjh.13131","article-title":"A large-scale computational study of inhibitor risk in non-severe haemophilia A","volume":"168","author":"Shepherd","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106649_bib54","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3270","article-title":"Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A","volume":"19","author":"Pandey","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.106649_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218258","article-title":"Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A","volume":"14","author":"Bachelet","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2026.106649_bib56","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jtha.2024.05.017","article-title":"Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network","volume":"22","author":"Jardim","year":"2024","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926033078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926033078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:21:36Z","timestamp":1784546496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926033078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2475037926033078"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106649","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Shaping hemophilia care: lessons and legacy of the SIPPET trial after 10 years","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106649"}}